Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NFkappaB and Bcl-X L.
Arginine deiminase (ADI) is known to be an inducer of apoptosis in vitro and an anti-tumor agent in vivo in some cancers. ADI causes the enzymatic depletion of arginine which may inhibit nitric oxide (NO) synthesis. However, the effect of ADI treatment on NO synthesis has not been clearly elucidated. With the goal of understanding the role of ADI in NO synthesis, we used the Ramos human lymphoma cell line, which is known to be ADI-sensitive. After determining an optimal experimental ADI concentration (0.001 U/ml), we studied the effects of ADI treatment when combined with different concentrations of the extrinsic NO donor, sodium nitroprusside (SNP) (i.e., control, ADI only, ADI with 10 microM/ml SNP, ADI with 50 microM/ml SNP, and ADI with 100 microM/ml SNP). An MTT assay was used to assess cell survival after treatment, nitric oxide assays to determine nitrite levels and Western blot analysis to determine the expression of the NO mediators, NFkappaB and Bcl-X L. Interestingly, we found that the extrinsic NO donor only partially reversed ADI-induced inhibition of cell growth in a dose-dependent pattern and resulted in an induction of NFkappaB and Bcl-X L expression. In conclusion, we suggest that there might be an association between reversal of cell growth inhibition by extrinsic NO donor with Bcl-X L and NFkappaB expression in ADI-treated Ramos cell.
Seo
Jae Hong
JH
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea.
Sung
Hwa Jung
HJ
Choi
Chul Won
CW
Kim
Byung Soo
BS
Shin
Sang Won
SW
Kim
Yeul Hong
YH
Min
Bon Hong
BH
Kim
Jun Suk
JS
D015153:Blotting, Western; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D006867:Hydrolases / Q000008:administration & dosage / Q000494:pharmacology*; D008223:Lymphoma / Q000378:metabolism / Q000473:pathology; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000008:administration & dosage / Q000494:pharmacology*; D009599:Nitroprusside / Q000008:administration & dosage / Q000494:pharmacology*; D051020:bcl-X Protein / Q000187:drug effects / Q000378:metabolism
C494811:BCL2L1 protein, human; D016328:NF-kappa B; D020030:Nitric Oxide Donors; D051020:bcl-X Protein; D009599:Nitroprusside; D009569:Nitric Oxide; D006867:Hydrolases; C019723:arginine deiminase